ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…<p><b>(A)</b> Top: behavioral timescales do not differ between different groups of participants (exp. 1 and 3/4) doing the same task; Bottom: Illustration of ECoG electrode placement for all subjects for both two location (left) and four location (right) tasks for the frontal, motor and parietal regions. …"

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" حسب Kira Shaw (18796168)

"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …"

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

All TPM values. حسب Hyuk Sung Yoon (20208672)

Values for all quantifications. حسب Sravya Paluri (5475260)

Numeric values used to generate all the graphs presented in the figures. حسب Wenjia Yu (9422059)

Table1_Leukocyte telomere length decreased the risk of mortality in patients with alcohol-associated liver disease.docx حسب Jiahong Yi (14481735)

"…</p>Results<p>LTL was a negative factor for all-cause mortality (all p-value < 0.05). The risk of cardiovascular disease (CVD)-related death was decreased in Q3 (p < 0.001) and Q4 levels of LTL (p < 0.001) compared with the Q1 group. …"

Numerical values underlying all Figs. حسب Juliana Zimmermann (10507091)

Innovation and night light in large and small cities. حسب Saul Estrin (8629173)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

The Ka/Ks values of PtWRKY paralogous gene pairs. حسب Yuzhao Ma (12840632)

الموضوعات: "…electrical conductivity decreased…"

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Table 1_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…This observational analysis aimed to explore the correlation between PNI levels and all-cause mortality (ACM) in patients undergoing prolonged glucocorticoid therapy for pneumonia.…"

Table 2_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…This observational analysis aimed to explore the correlation between PNI levels and all-cause mortality (ACM) in patients undergoing prolonged glucocorticoid therapy for pneumonia.…"

Table 3_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx حسب Fengwang Xue (22245625)

"…This observational analysis aimed to explore the correlation between PNI levels and all-cause mortality (ACM) in patients undergoing prolonged glucocorticoid therapy for pneumonia.…"